Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
Jani Huuhtanen, Henna H.E. Kasanen, Katriina Peltola, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 6
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Advances in single-cell RNA sequencing and its applications in cancer research
Dezhi Huang, Naya Ma, Xinlei Li, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 83
LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity
Lawrence P. Andrews, Samuel C. Butler, Jian Cui, et al.
Cell (2024) Vol. 187, Iss. 16, pp. 4355-4372.e22
Closed Access | Times Cited: 59
Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity
Anthony R. Cillo, Carly Cardello, Feng Shan, et al.
Cell (2024) Vol. 187, Iss. 16, pp. 4373-4388.e15
Closed Access | Times Cited: 42
Clinical and translational attributes of immune-related adverse events
Karijn P.M. Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, et al.
Nature Cancer (2024) Vol. 5, Iss. 4, pp. 557-571
Closed Access | Times Cited: 38
LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity
Shin Foong Ngiow, Sasikanth Manne, Yinghui Huang, et al.
Cell (2024) Vol. 187, Iss. 16, pp. 4336-4354.e19
Closed Access | Times Cited: 26
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Dia Roy, Cassandra Gilmour, Sachin Patnaik, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
Developments and future prospects of personalized medicine in head and neck squamous cell carcinoma diagnoses and treatments
Shalindu Malshan Jayawickrama, Piyumi Madhushani Ranaweera, Roshan Pradeep, et al.
Cancer Reports (2024) Vol. 7, Iss. 3
Open Access | Times Cited: 8
Targeting CD8+ T cells with natural products for tumor therapy: Revealing insights into the mechanisms
Yuke Wang, Yan Zeng, Wenyong Yang, et al.
Phytomedicine (2024) Vol. 129, pp. 155608-155608
Closed Access | Times Cited: 8
LAG‐3 : recent developments in combinational therapies in cancer
Aude Chavanton, Flavie Mialhe, Jimena Abrey, et al.
Cancer Science (2024) Vol. 115, Iss. 8, pp. 2494-2505
Open Access | Times Cited: 8
Tumor-infiltrating γδ T cells as targets of immune checkpoint blockade in melanoma
Marta Di Simone, Anna Maria Corsale, Francesca Toia, et al.
Journal of Leukocyte Biology (2024) Vol. 115, Iss. 4, pp. 760-770
Closed Access | Times Cited: 7
Advances in Melanoma: From Genetic Insights to Therapeutic Innovations
Fernando Valdez-Salazar, Luis Alberto Jiménez-Del Río, Jorge Ramón Padilla‐Gutiérrez, et al.
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1851-1851
Open Access | Times Cited: 7
Single-cell analysis unveils cell subtypes of acral melanoma cells at the early and late differentiation stages
Mengyuan Hou, Zhijie Zhao, Songbai Zhu, et al.
Journal of Cancer (2024) Vol. 16, Iss. 3, pp. 898-916
Open Access | Times Cited: 6
The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis
Yifan Zeng, Xinyu Wei, Qihao Guo, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Advancement of anti‐LAG‐3 in cancer therapy
Yunong Li, Mingyi Ju, Yuxi Miao, et al.
The FASEB Journal (2023) Vol. 37, Iss. 11
Closed Access | Times Cited: 11
Prediction of immunotherapy responsiveness in melanoma through single-cell sequencing-based characterization of the tumor immune microenvironment
Yucheng Dong, Zhizhuo Chen, Fan Yang, et al.
Translational Oncology (2024) Vol. 43, pp. 101910-101910
Open Access | Times Cited: 4
Akkermania muciniphila: a rising star in tumor immunology
Leihan Wang, Dong Tang
Clinical & Translational Oncology (2024) Vol. 26, Iss. 10, pp. 2418-2430
Closed Access | Times Cited: 4
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020
Paolo A. Ascierto, Hao Tang, Sonia Dolfi, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e009773-e009773
Open Access
New insights into cancer immune checkpoints landscape from single-cell RNA sequencing
Qian Wang, Jiahui He, Tianyu Lei, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025) Vol. 1880, Iss. 3, pp. 189298-189298
Closed Access
Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies
Zhiwei Han, Guomin Chen, Dongchen Wang
Frontiers in Immunology (2025) Vol. 16
Open Access
Efficacy of anti-LAG3 and anti-PD-1 combination checkpoint inhibitor therapy against head and neck squamous cell carcinoma in a genetically engineered mouse model
Felipe Lamenza, Peyton Roth, Puja Upadhaya, et al.
OncoImmunology (2025) Vol. 14, Iss. 1
Open Access
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer
Miaomiao Chen, Yuli Zhou, Kelvin K H Bao, et al.
BioDrugs (2025)
Closed Access
Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors
Piotr Wawrzyniak, Mariusz L. Hartman
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
The response to anti–PD-1 and anti–LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming
Annah S. Rolig, Xiyu Peng, Elizabeth R. Sturgill, et al.
Science Translational Medicine (2025) Vol. 17, Iss. 793
Closed Access
CD8+ T Cell Subsets as Biomarkers for Predicting Checkpoint Therapy Outcomes in Cancer Immunotherapy
Rosaely Casalegno‐Garduño, Alf Spitschak, Tim Pannek, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 930-930
Open Access
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
Gusztav Milotay, Martin Little, Robert Watson, et al.
Nature Medicine (2025)
Open Access
Page 1 - Next Page

Scroll to top